Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor plus (HR+), HER2-metastatic breast cancer (MBC) not previously treated with a taxane.

被引：1

作者：

Schwartzberg, Lee S.

Bondarenko, Igor

Tolaney, Sara M.

Seidman, Andrew David

O'Shaughnessy, Joyce

Shparyk, Yaroslav V.

Chung, Chi-Feng

Lu, Yen-Shen

Chic, Nuria

Panasci, Lawrence C.

Chae, Yee Soo

Recalde, Sabela

Hotko, Yevhen

Gomez, Patricia

Shaw Wright, Gail Lynn

Anthony Dacosta, Noshir

Vatandoust, Sina

O'Connell, Joseph P.

Wei, Thomas

Rugo, Hope S.

机构：

[1] West Canc Ctr, Memphis, TN USA

[2] City Clin Hosp 4, Dnipro, Ukraine

[3] Dana Farber Canc Inst, Boston, MA USA

[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[5] US Oncol, Texas Oncol Baylor Sammons Canc Ctr, Dallas, TX USA

[6] Lviv State Oncol Reg Med & Diagnost Ctr, Lvov, Ukraine

[7] Koo Fdn Sun Yat Sen Canc Ctr, Taipei, Taiwan

[8] Natl Taiwan Univ Hosp, Taipei, Taiwan

[9] Hosp Clin Barcelona, Barcelona, Spain

[10] Jewish Gen Hosp, Montreal, PQ, Canada

[11] Kyungpook Natl Univ Hosp, Daegu, South Korea

[12] Inst Catala Oncol Hosp Duran & Reynals, Barcelona, Spain

[13] Uzhgorod Natl Univ, Uzhgorod, Ukraine

[14] Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Barcelona, Spain

[15] Sarah Cannon Res Inst & Florida Canc Specialists, New Port Richey, FL USA

[16] North Shore Hematol Oncol Associates, Stony Brook, NY USA

[17] Flinders Univ S Australia, Flinders Med Ctr, Adelaide, SA, Australia

[18] Odonate Therapeut Inc, San Diego, CA USA

[19] Univ Calif San Francisco, San Francisco, CA 94143 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.1061

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1061

引用

页数：3

共 50 条

[1] CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane
Schwartzberg, Lee
Asselah, Jamil
Bondarenko, Igor
Chae, YeeSoo
DaCosta, Noshir
Feng, Yin-Hsun
Izarzugaza, Yann
Lemieux, Julie
Liu, Mei-Ching
Marx, Gavin
O'Shaughnessy, Joyce
Oliveira, Mafalda
Rugo, Hope
Seidman, Andrew
Wright, Gail
O'Connell, Joseph
Wei, Thomas
Kim, Sung-Bae
CANCER RESEARCH, 2020, 80 (04)
[2] CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor plus (HR plus ) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane.
O'Shaughnessy, Joyce
Piccart, Martine
Schwartzberg, Lee S.
Cortes, Javier
Harbeck, Nadia
Im, Seock-Ah
Rugo, Hope S.
Untch, Michael
Yardley, Denise A.
Bondarenko, Igor
Chan, Stephen
Dieras, Veronique
Pegram, Mark D.
Kroll, Stew
O'Connell, Joseph P.
Vacirca, Jeff
Wei, Thomas
Tang, Kevin
Seidman, Andrew David
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[3] CONTESSA: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane
O'Shaughnessy, Joyce
Piccart, Martine
Schwartzberg, Lee
Cortes, Javier
Harbeck, Nadia
Im, Seock-Ah
Rugo, Hope
Untch, Michael
Yardley, Denise
Bondarenko, Igor
Dieras, Veronique
Pegram, Mark
Kroll, Stew
O'Connell, Joseph
Vacirca, Jeff
Wei, Thomas
Tang, Kevin
Seidman, Andrew
CANCER RESEARCH, 2020, 80 (04)
[4] Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane
O'Shaughnessy, Joyce
Schwartzberg, Lee
Piccart, Martine
Rugo, Hope S.
Yardley, Denise A.
Cortes, Javier
Untch, Michael
Harbeck, Nadia
Wright, Gail S.
Bondarenko, Igor
Glaspy, John
Nowecki, Zbigniew
Kayali, Fadi
Chan, Arlene
Levy, Christelle
Liu, Mei-Ching
Kim, Sung-Bae
Lemieux, Julie
Manikhas, Alexey
Tolaney, Sara
Lim, Elaine
Gombos, Andrea
Stradella, Agostina
Pegram, Mark
Fasching, Peter
Mangel, Laszlo
Semiglazov, Vladimir
Dieras, Veronique
Gianni, Luca
Danso, Michael A.
Vacirca, Jeff
Kroll, Stew
O'Connell, Joseph
Tang, Kevin
Wei, Thomas
Seidman, Andrew
CANCER RESEARCH, 2021, 81 (04)
[5] Contessa: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel in patients (Pts) with HER2-, hormone receptor plus (HR plus ) locally advanced or metastatic breast cancer (MBC).
O'Shaughnessy, Joyce
Piccart-Gebhart, Martine J.
Schwartzberg, Lee Steven
Cortes, Javier
Harbeck, Nadia
Im, Seock-Ah
Rugo, Hope S.
Untch, Michael
Yardley, Denise A.
Bondarenko, Igor
Chan, Stephen
Dieras, Veronique
Gianni, Luca
Pegram, Mark D.
Kroll, Stew
O'Connell, Joseph P.
Vacirca, Jeffrey L.
Wei, Thomas
Tang, Kevin
Seidman, Andrew David
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[6] Results From CONTESSA: A Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2-, Hormone Receptor+ Metastatic Breast Cancer Who Have Previously Received a Taxane
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 9 - 10
[7] Results From CONTESSA: A Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2-, Hormone Receptor+ Metastatic Breast Cancer Who Have Previously Received a Taxane
O'Shaughnessy, Joyce
Schwartzberg, Lee
Piccart, Martine
Rugo, Hope S.
Yardley, Denise A.
Cortes, Javier
Untch, Michael
Harbeck, Nadia
Wright, Gail S.
Bondarenko, Igor
Glaspy, John
Nowecki, Zbigniew
Kayali, Fadi
Chan, Arlene
Levy, Christelle
Liu, Mei-Ching
Kim, Sung-Bae
Lemieux, Julie
Manikhas, Alexey
Tolaney, Sara
Lim, Elaine
Gombos, Andrea
Stradella, Agostina
Pegram, Mark
Fasching, Peter
Mangel, Laszlo
Semiglazov, Vladimir
Dieras, Veronique
Gianni, Luca
Danso, Michael A.
Vacirca, Jeff
Kroll, Stew
O'Connell, Joseph
Tang, Kevin
Wei, Thomas
Seidman, Andrew
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 12 - 13
[8] CONTESSA TRIO: A multinational, multicenter, phase (P) II study of tesetaxel (T) plus three different PD-(L)1 inhibitors in patients (Pts) with metastatic triplenegative breast cancer (TNBC) and tesetaxel monotherapy in elderly pts with HER2-metastatic breast cancer (MBC).
Tolaney, Sara M.
Bondarenko, Igor
Chan, Arlene
Dacosta, Noshir Anthony
Izarzugaza, Yann
Kim, Gun Min
Liu, Mei-Ching
Perez, Maria Eva
Lu, Yen-Shen
Oliveira, Mafalda
Ow, Samuel Guan Wei
Pavic, Michel
Rugo, Hope S.
Schwartzberg, Lee S.
Stradella, Agostina
Tan, Tira Jing Ying
Wright-Browne, Vance
O'Connell, Joseph P.
Wei, Thomas
Mittendorf, Elizabeth A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[9] Activity of tesetaxel, an oral taxane, given as a single-agent in patients (Pts) with HER2-, hormone receptor plus (HR plus ) locally advanced or metastatic breast cancer (MBC) in a phase 2 study
Seidman, Andrew David
Schwartzberg, Lee Steven
Gudena, Vinay K.
Rubin, Peter
Kroll, Stew
O'Connell, Joseph P.
Tang, Kevin
O'Shaughnessy, Joyce
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[10] Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in women with previously treated hormone receptor-positive (HR+), HER2-metastatic breast cancer
Dieras, V.
Hamilton, E.
Johnston, E. L.
Forrester, T.
Martin, M.
CANCER RESEARCH, 2017, 77

← 1 2 3 4 5 →